The Relative Strength (RS) Rating for Sanofi ADR climbed into a new percentile Monday, with a rise from 76 to 84.
This proprietary rating identifies market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of other stocks on the major indexes.
History shows that the stocks that go on to make the biggest gains tend to have an RS Rating north of 80 as they begin their biggest runs.
Looking For The Best Stocks To Buy And Watch? Start Here
While Sanofi ADR is not near a proper entry right now, see if it goes on to form and break out of a proper chart pattern.
The company posted -29% EPS growth last quarter. Sales rose 2%. The company is expected to report its latest earnings and sales numbers on or around Apr. 24.
Sanofi ADR holds the No. 5 rank among its peers in the Medical-Ethical Drugs industry group. Novartis ADR is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
